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Alport syndrome (AS) is caused by pathogenic mutations in the genes
encoding α3, α4 or α5 chains of collagen IV (COL4A3/COL4A4/COL4A5),
resulting in hematuria, chronic renal failure (CRF), sensorineural hearing
loss (SNHL) and ocular abnormalities. Mutations in the X-linked COL4A5
gene have been identified in 85% of the families (XLAS). In this study, 22 of
60 probands (37%) of unrelated Portuguese families, with clinical diagnosis
of AS and no evidence of autosomal inheritance, had pathogenic COL4A5
mutations detected by Sanger sequencing and/or multiplex-ligation probe
amplification, of which 12 (57%) are novel. Males had more severe and
earlier renal and extrarenal complications, but microscopic hematuria was a
constant finding irrespective of gender. Nonsense and splice site mutations,
as well as small and large deletions, were associated with younger age of
onset of SNHL in males, and with higher risk of CRF and SNHL in females.
Pathogenic COL4A3 or COL4A4 mutations were subsequently identified in
more than half of the families without a pathogenic mutation in COL4A5.
The lower than expected prevalence of XLAS in Portuguese families
warrants the use of next-generation sequencing for simultaneous
COL4A3/COL4A4/COL4A5 analysis, as first-tier approach to the genetic
diagnosis of collagen type IV-related nephropathies.
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Alport syndrome (AS) is caused by pathogenic muta-
tions in the genes encoding the α5, α4 or α3 type
IV collagen chains (1, 2), respectively, COL4A5,
COL4A4 and COL4A3. The selective tissue expres-
sion of α5α4α3(IV) heterotrimers explains the renal,
cochlear and ocular involvement of AS. Although
rare, AS represents an important cause of end-stage
renal failure (ESRF), particularly among young
adults (1).
In patients with hematuria of uncertain etiology, the
clinical diagnosis of AS can be established whenever
at least three of the following criteria are fulfilled (3):
family history of macro/microscopic hematuria and/or
chronic renal failure (CRF); typical glomerular base-
ment membrane (GBM) lesions on electron microscopy
examination; high tone sensorineural hearing loss
(SNHL); characteristic ocular abnormalities (anterior
lenticonus and/or white macular flecks). Immunohisto-
chemical analysis of expression α5(IV) in the epidermal
basement membrane and/or of α5α4α3(IV) in the GBM
are additional AS diagnostic tools (2, 3). However,
genetic testing has been accepted as the gold standard
for the diagnosis of AS and demonstration of its mode
of inheritance (2).
About 85% of AS families (1) carry pathogenic
COL4A5 mutations, causing the X-linked form of the
disease (XLAS; MIM#301050). Moreover, AS with dif-
fuse leiomyomatosis (ATS-DL; MIM#308940) and AS
with mental retardation, midface hypoplasia and ellip-
tocytosis (AMME; MIM#300194) are two rare syn-
dromes caused bymicrodeletions involvingCOL4A5 (1).
The remainder of cases, which are due to pathogenic
COL4A3 and/or COL4A4 mutations, are inherited as
autosomal recessive (ARAS; MIM#2013780) or dom-
inant (ADAS; MIM#104200) disorders. Heterozygous
COL4A3 orCOL4A4mutations are identified in 40–50%
of patients with thin basement membrane nephropathy
(TBMN; MIM#141200).
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More than 700 disease-causing COL4A5 mutations,
most of them unique to single families, have already been
described (4). Whereas in hemizygous males, complex
rearrangements, large and small deletions, nonsense and
splice site mutations are associated with more severe
phenotype and worse prognosis (5–7), no significant
genotype–phenotype correlations could be identified in
heterozygous females (8).
The data available on the molecular pathology of AS in
Portugal were from a small number of families enrolled
on a European collaborative study (6, 8). Our major goals
are, therefore, to describe the genetic epidemiology and
genotype–phenotype correlations in a large nationwide
cohort of Portuguese families diagnosed with AS.
Patients and methods
Between 1 January 2009 and 30 June 2012, 60 unrelated
patients with at least one of the diagnostic criterion
of AS (3), and their affected or at-risk relatives who
accepted genetic evaluation, were enrolled in this study
for COL4A5 mutational analysis. The research protocol
was approved by the Health Ethics Commission of São
João Hospital Centre (Porto; Portugal).
The relevant clinical data were collected at enrolment
by the referring physician, using a standardized ques-
tionnaire. Additional data were retrospectively collected
by review of archive medical records, or interviewing
patient’s relatives. Respectively 5 (8.3%), 17 (28.3%),
26 (43.3%) and 12 (20%) of the probands fulfilled four,
three, two and one diagnostic criteria, in addition to
hematuria.
Genomic DNA was extracted from whole blood
samples. All 53 exons of COL4A5 and corresponding
exon/intron boundaries were amplified by polymerase
chain reaction (PCR), using previously described
primers and conditions (9). The PCR products were
analyzed by Sanger DNA sequencing, using routine lab-
oratory protocols and standard capillary electrophoresis.
In addition, a commercial multiplex ligation-dependent
probe amplification (MLPA) assay was used to scan for
large deletions/duplications involving COL4A5 and the
5′ region of COL4A6. Novel variants were considered
pathogenic on the basis of molecular, epidemiological,
family segregation and/or bioinformatic criteria, as sum-
marized in Table S1, Supporting Information. Whenever
a novel COL4A5 variant of uncertain pathogenicity was
identified, or a pathogenic COL4A5 mutation could not
be identified in the proband, COL4A3 and COL4A4were
subsequently scanned for pathogenic mutations (20).
Parental genotyping was carried out, whenever possi-
ble, to confirm whether the COL4A5 mutation identified
in a proband was inherited or de novo. In cases where
the same novel mutation was identified in apparently
unrelated probands, microsatellite polymorphic markers
flanking the COL4A5-COL4A6 genes were used for hap-
lotype analysis, as previously described (10, 11).
For genotype–phenotype correlation analyses,
COL4A5 mutations were grouped according to the
expected severity of the corresponding phenotype
(7). Outcomes were compared between genders and,
within each gender, between patients with large rear-
rangements, frameshifting, nonsense or splice donor
mutations (‘severe’ mutations), and those with other
types of mutations (‘severe/moderate’ mutations). To
minimize ascertainment bias, the clinical phenotypes
per gender and the genotype–phenotype correlations
were analyzed in ‘phenotyping cohorts’, comprising
the probands and their affected relatives subsequently
enrolled in this study.
Parametric and non-parametric statistics were used, as
appropriate, for comparisons of demographic variables
and clinical outcomes. The data were analyzed with the
ibm spss Statistics software version 21 (IBM Corpora-
tion; Armonk, NY).Results
Twenty-two (37%) of the 60 probands had a pathogenic
mutation in COL4A5, of which 12 (57%) were novel and
9 (43%) had been previously described (Table 1) (5, 9,
12–17). Eighty percent of the probands who presented
with all four diagnostic criteria, but only 1 of 3 of
those who presented with two or three criteria, had a
pathogenic mutation in COL4A5. Missense substitutions
(7/21; 33%), all involving glycine residues, were the
most common type of mutation. The novel c.4342G>C
(p.Gly1448Arg) missense mutation was identified in
two apparently unrelated probands; in the two families,
living in neighboring towns, the pathogenic mutation
segregated with the same microsatellite haplotype. In 2
of 13 (15%) genetic probands, theCOL4A5mutation was
proven to be de novo by parental genotyping.
The identification of a pathogenic COL4A5 mutation
allowed confirmation of XLAS in 43 more patients from
the 22 families, increasing the size of the phenotyping
cohorts to 30 males (46%; mean age 36± 16.8 years)
and 35 females (54%; mean age 42± 14.8 years). Those
two cohorts are described and compared in Table 1.
Only two-thirds of the patients had undergone audiolog-
ical assessment and less than 60% had been referred for
specialized ophthalmological examination. This shows
that appropriate screening for the extrarenal signs of AS
is frequently overlooked in clinical practice (3), which
might influence the diagnostic judgment. Expression of
renal disease in the male cohort did not substantially
differ from the usual description of XLAS in males
(6); however, the prevalence of chronic kidney disease
(CKD) in the female cohort was higher than previously
reported (8). Microscopic hematuria was present in all
cases, irrespective of gender. The risks of developing
progressive CKD and ESRF were considerably higher
in males (p= 0.029 and p< 0.001, respectively). Nev-
ertheless, CKD was diagnosed in 62% of the heterozy-
gous females, at young adult age in many cases. Elec-
tron micrographs of kidney biopsies, available from nine
patients, showed the typical ultrastructural features of
AS, irrespective of gender. Subjective hearing loss was
more often reported by males (87% vs 46%; p= 0.001).
Anterior lenticonus and dot-and-fleck retinopathy were
also more frequently diagnosed in males (p= 0.013 and
p= 0.129, respectively). ATS-DL was diagnosed in one
family, in association with a large deletion involving
COL4A5, but not the COL4A6 gene (13).
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Table 1. Phenotypic comparisons between hemizygous males and heterozygous females for pathogenic COL4A5 mutations (n= 65)
Hemizygotes (n= 30) Heterozygotes (n=35) p-value
N N
Phenotype




30 42 (14.8) 35 0.088
History of renal abnormalities
History of macroscopic hematuria (%) 61.9 13/21 17.4 4/23 0.002
Age at diagnosis [median (interquartile
range)]
5 (4) 11 3 (11.5a) 3 0.501
History of microscopic hematuria (%) 100.0 25/25 100.0 35/35 b
Age at diagnosis [median (interquartile range)] 12.5
(20.3)
22 21 (26.5) 28 0.219
History of proteinuria (%) 96.2 25/26 78.8 26/33 0.067
Age at diagnosis [median (interquartile
range)]
18 (22.5) 21 24 (19) 23 0.508
History of hypertension (%) 73.1 19/26 52.9 18/34 0.112
Age at diagnosis [median (interquartile
range)]
20 (11.5) 12 34 (22.3) 16 0.002
History of CKD stage 2 or higher (%) 86.2 25/29 61.8 21/34 0.029
Age at diagnosis [median (interquartile
range)]
21 (10) 16 32 (17.5) 20 0.038
History of renal replacement therapy (%) 76.7 23/30 17.1 6/35 <0.001
Age at onset [median (interquartile range)] 23 (19.5) 21 40 (14) 6 0.272
GBM ultrastructural abnormalities 100.0 6/6 100.0 3/3 b
Age at kidney biopsy [median (interquartile
range)]
20 (14.5) 6 24 (11a) 3 0.933
Hearing loss
Self-noticed or subjective (%) 86.7 26/30 45.5 15/33 0.001
Age at self-noticed or subjective [median
(interquartile range)]
15 (30) 15 39 (19) 9 0.142
Audiogram (%) 94.1 16/17 91.3 21/23 0.053
Age at diagnosis of hearing loss by
audiogram [median (interquartile range)]
27.5 (18) 16 41 (10) 13 0.030
Ocular abnormalities
Anterior lenticonus (%) 33.3 5/15 0.0 0/18 0.013
Age at diagnosis [median (interquartile
range)]
19 (12) 5 – – –
Maculopathy (%) 50.0 10/20 26.3 5/19 0.129
Age at diagnosis [median (interquartile
range)]
25 (19) 8 44 (22) 5 0.180
Cataracts (%) 46.2 6/13 15.0 3/20 0.107
Age at diagnosis [median (interquartile
range)]
30 (35.8) 6 56 (56a) 3 0.263
Other abnormalities
Leiomyomatosis (%) 3.3 1/30 5.7 2/35 1.000
Age at diagnosis [median (interquartile
range)]
24 1 18 1 0.317
Genotype
Truncating mutation (%) 47 14/30 37.1 13/35 0.437
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; GBM, glomerular basement membrane; SD, standard
deviation. Age is expressed in years. eGFR is expressed in ml/min/1.73m2.
aThe range is indicated instead of the interquartile range.
bStatistics not computed because the proportions in the comparison groups are the same.
In contrast to previous studies (5–7), we did not iden-
tify any significant differences on prevalence or severity
of expression of renal disease between males carrying
‘severe’ or ‘severe/moderate’ COL4A5 mutations,
although they manifested more severe extrarenal
phenotypes. Conversely, the higher prevalence of
CRF and SNHL in females with ‘severe’ COL4A5
mutations (Table S2) was not apparent in the largest
study of females with XLAS reported so far (8). This
genotype–phenotype correlation might have become
apparent in our cohort as result of the enrolment of
females with more severe renal phenotypes.
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Discussion
This is the first study to report the clinical fea-
tures, molecular pathology and genotype–phenotype
correlations observed in a large number of Portuguese
patients with genetically confirmed XLAS. A causative
COL4A5 mutation was identified in 36.7% (22/60) of
the probands. Although this mutation detection rate
was significantly lower than expected, it cannot be
explained by limitations of the molecular approach,
as the sensitivity of Sanger sequencing combined with
MLPA to identify COL4A5 mutations is higher than
90% (2, 3). Because we did not exclude enrolment of
probands/families without extrarenal manifestations,
and the latter are less common in ADAS and absent
in TBMN (18), the major explanation for these results
can be the higher relative prevalence of autosomal
forms of collagen type IV-related GBM nephropathies
in Portuguese families with clinical diagnosis of AS
(20). Our data are in agreement with those of a recent
Italian study that reported the diagnosis of XLAS in
only 2 out of 3 of families with AS confirmed by unbi-
ased next generation sequencing (NGS) (19). Taken
together, these observations suggest that the relative
prevalence of XLAS in Southern European popula-
tions may be lower than the usual estimates in the
literature (1).
Because of the heterogeneity of the collagen type
IV-related GBM nephropathies, clinicians should
also take a detailed three-generation family history
in order to try to recognize the pattern of inheri-
tance before initiating genetic testing for XLAS (3).
Nonetheless, it should be recognized that XLAS
and ARAS may be difficult to distinguish in an
affected male with a small pedigree and that some
hypomorphic COL4A5 mutations may manifest with
microscopic hematuria, with or without ESRF, but with
no SNHL or ocular involvement, thereby mimicking
TBMN (1).
Identification of a pathogenic COL4A5 mutation is the
most specific criterion for diagnosis of XLAS, avoiding
the need for kidney and/or skin biopsies. It is pivotal for
family screening and pre-symptomatic diagnosis, with
obvious implications for genetic counseling; estimation
of the clinical prognosis; selection of living related
female donors for kidney transplantation; and prenatal
and pre-implantation diagnosis. Genetic diagnosis may
also permit the earlier institution of effective nephro-
protective therapies, particularly by renin–angiotensin
system blockade (2).
However, Sanger sequencing of all 53 COL4A5
exons and flanking intronic sequences is a labori-
ous, time-consuming and expensive process. The
recent availability of benchtop NGS platforms has
offered the possibility to simultaneously analyze the
COL4A5/COL4A4/COL4A3 genes at cheaper costs
and with much lower turn-around times (19). This
may become the first-tier genetic testing strategy to
confirm the diagnosis of AS, particularly in populations
where the prevalence of XLAS is not much higher than
that of the autosomal forms.
Supporting Information
Additional supporting information may be found in the online
version of this article at the publisher’s web-site.
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